• Cellvizio®
    • Overview
    • Education
    • Economics
  • Indications
    • Gastroenterology
      • Barrett’s Esophagus
      • Pancreatic Cystic Lesions
      • Gastric Disease
      • Inflammatory Bowel Diseases
      • Irritable Bowel Syndrome – Food Intolerance
      • Bilio-Pancreatic Strictures
      • Colorectal Lesions
    • Pulmonology
      • Lung Nodules
      • Lung Transplant
    • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Regulated Information
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

by Elizabeth | Jul 10, 2025

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure 

by Elizabeth | Jul 10, 2025

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

Publication of the 2024 Annual Financial Report 

by Elizabeth | Apr 30, 2025

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

2024 Annual Financial Report (free translation)

by Elizabeth | Apr 30, 2025

Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure 

Full Year 2024 Sales 

by Elizabeth | Apr 24, 2025

« Older Entries
Next Entries »

Articles récents

  • PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 
  • Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 
  • Earlier, More Accurate Detection of Pancreatic Cancer
  • Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 
  • Mauna Kea Technologies Announces 2026 Half-Year Results 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}